Fig. 1.

Graphical summary of the Asia-Pacific multidisciplinary panel recommendations for the monitoring and management of T-DXd–related adverse events in patients with metastatic breast cancer. ^aSigns and symptoms of ILD/pneumonitis may include cough, dyspnoea, fever and other new or worsening respiratory symptoms. ^bJunior doctors and breast care nurses may also be included. ^c6-min walk test or 1-minute sit-to-stand tests. ^dComplete workup is recommended upon signs and symptoms of anaemia. ^eSuch as anaemia. ^fSuch as echocardiography and other laboratory tests. 5-HT3 serotonin receptor antagonists CBC complete blood count, CT computed tomography, DEX dexamethasone, G-CSF granulocyte colony-stimulating factor, HRCT high-resolution computed tomography, ILD interstitial lung disease, IV intravenous, LVEF left ventricular ejection fraction, NK1 neurokinin 1 antagonists, PI prescribing information, RBC red blood cell, SpO₂ Oxygen saturation measured by pulse oximetry, T-DXd trastuzumab deruxtecan